Combination treatment for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy, targeted therapy, and immunotherapy, with or without radiation to the primary tumor, for people with advanced rectal cancer that has a specific genetic profile. It aims to see if adding radiation improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that has spread to other parts of the body (stage IV).
- Your tumor has a KRAS or NRAS mutation but not a BRAF V600 mutation, and is pMMR (a specific protein marker).
- You have not had previous chemotherapy for metastatic disease, or you had only one cycle of FOLFOX or CAPOX and have not been evaluated for response yet.
- You have at least one measurable tumor lesion and your primary tumor is still present (no prior radiation to it).
- You are in good general health (ECOG score 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and radiation before surgery for people with a specific type of high-risk rectal cancer. The goal is to see if adding these drugs can improve treatment results.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial tests a combination of radiation therapy with three drugs (an immunotherapy, a chemotherapy pill, and a targeted therapy) for advanced colorectal cancer. It aims to see if this combination can shrink tumors and improve outcomes for people whose cancer has not responded to standard treatments.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy and bevacizumab before surgery can shrink rectal tumors and improve outcomes. It is designed for people with locally advanced rectal cancer that has not spread to distant organs, and the treatment is given as a first step before the main surgery.
This study tests a new combination of drugs and targeted radiation for people with advanced colorectal cancer that has spread to a few spots. It aims to see if this approach works better than the current standard treatment after other therapies have failed.
Hear when a new Rectal Neoplasms Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.